Roivant Sciences Ltd
Research Roivant Sciences Ltd (ROIV) on Bullrun: market cap USD 25.61B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerROIV
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 25.61B
- Financial periodFY2026
- RevenueUSD 8.26M
- Revenue growth-71.6%
- Net income-USD 299.77M
- Free cash flow-USD 758.56M
- Gross margin84.4%
Valuation Snapshot
latest market cap is USD 25.61B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 8.26M | -USD 299.77M | -USD 758.56M | 84.4% | -0.54 | USD 1.42B | USD 107.44M | USD 4.53B |
| FY2025 | USD 29.05M | -USD 171.98M | -USD 844.05M | 96.9% | -0.24 | USD 2.72B | USD 100.17M | USD 4.69B |
| FY2024 | USD 32.71M | USD 4.35B | -USD 766.65M | 95.1% | 5.23 | USD 6.49B | USD 442.59M | USD 5.97B |
| FY2023 | USD 31.53M | -USD 1.01B | -USD 856.08M | 90.4% | -1.42 | USD 1.68B | USD 416.24M | USD 1.16B |
| FY2022 | USD 55.29M | -USD 845.26M | -USD 695.17M | 83.8% | -1.26 | USD 2.06B | USD 210.03M | USD 1.66B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 25.61B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.40B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.51B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.03B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.80B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 6.98B | n/a | n/a | n/a |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease;
ETFs that hold Roivant Sciences Ltd
Roivant Sciences Ltd is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 1.74% | 0.35% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.66% | 0.40% |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 1.73% | 0.35% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Roivant Sciences Ltd's market cap?
Roivant Sciences Ltd's market capitalization is USD 25.61B.
What does Roivant Sciences Ltd do?
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.